DNLI Q1 2024 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$118M

Net Income

-$102M

EPS (Diluted)

$-0.68

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$114M

Free Cash Flow

-$116M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$126M

Stockholders' Equity

$1.5B

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$35M	-100.0%
Gross Profit	$0	$35M	-100.0%
Operating Income	-$118M	-$121M	+2.6%
Net Income	-$102M	-$110M	+7.3%